International ScaleNormalized Copy Number values of Major BCR-ABL1 fusion gene (p210 transcript), haematological parameters and Lactate Dehydrogenase activity in Chronic Myeloid Leukaemia patients: A comparative study from Western India

Chronic Myeloid Leukaemia patients (CML) with presence of Breakpoint Cluster Region-Abelson (BCR-ABL) gene rearrangement [t (9; 22) (q34; q11)] predicts response to targeted therapy and survival.Hence, this study intends to explore clinical relevance of Major BCR-ABL fusion gene (MBCR-ABL) expression in CML patients and validate %NCN (Normalized copy number) with %IS-NCN (Normalized copy number on international scale).Fifty haematologically & cytogenetically confirmed CML patients were enrolled.Total RNA was extracted from blood samples and was reverse transcribed to cDNA followed by quantification of MBCR-ABL1 transcript by real time PCR.Statistical analysis was done by SPSS software.Fifty CML patients, included 15 untreated (UT) patients, 15 treatment non-responders (TNRs) and 20 treatment responders (TRs).MBCR-ABL1 expression decreased across groups, with TRs showing the lowest averages, suggesting progression towards major molecular response.CML patients with abnormal haematological parameters trended higher expression levels of MBCR-ABL1 across all groups.Combining MBCR-ABL1 fusion gene analysis with traditional cytogenetic and haematological assessments, enhances disease monitoring and more timely interventions towards improved outcomes in managing CML.Moreover, the %NCN correspond to the IS-NCN values of M-BCR-ABL fusion gene, haematological parameters and Lactate dehydrogenase (LDH) values, which are useful in diagnosis and monitoring treatment response and management of CML patients during follow up.